{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:20:18Z","timestamp":1762431618241,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","award":["C1034211"],"award-info":[{"award-number":["C1034211"]}],"id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clbc.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T02:19:19Z","timestamp":1555553959000},"page":"e624-e636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia"],"prefix":"10.1016","volume":"19","author":[{"given":"Qinghua","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningchao","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7790-8197","authenticated-orcid":false,"given":"Kutty Selva","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2019.04.006_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1358\/dot.2016.52.9.2525739","article-title":"Combination therapies for improved management of lower urinary tract symptoms\/benign prostatic hyperplasia","volume":"52","author":"De Nunzio","year":"2016","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.clbc.2019.04.006_bib2","first-page":"2382","article-title":"BPH\/LUTS and ED: common pharmacological pathways for a common treatment","volume":"10","author":"Fusco","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/nau.21246","article-title":"Mechanisms of action of botulinum neurotoxins, beta(3)-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011","volume":"31","author":"Kanai","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.clbc.2019.04.006_bib4","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1097\/MD.0000000000000974","article-title":"Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"94","author":"Yuan","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clbc.2019.04.006_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/09546634.2013.813011","article-title":"The efficacy and safety of 5 alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride","volume":"25","author":"Gupta","year":"2014","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.clbc.2019.04.006_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/andr.12353","article-title":"Sexual dysfunction in subjects treated with inhibitors of 5\u03b1-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis","volume":"5","author":"Corona","year":"2017","journal-title":"Andrology"},{"key":"10.1016\/j.clbc.2019.04.006_bib7","first-page":"1554","article-title":"Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis","volume":"11","author":"Gacci","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/jc.2006-2203","article-title":"The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men","volume":"92","author":"Amory","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clbc.2019.04.006_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.fertnstert.2013.07.2000","article-title":"Finasteride use in the male infertility population: effects on semen and hormone parameters","volume":"100","author":"Samplaski","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clbc.2019.04.006_bib10","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1742-1241.2012.03010.x","article-title":"A\u00a05-year retrospective analysis of 5\u03b1-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride","volume":"66","author":"Kaplan","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clbc.2019.04.006_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0974-7753.51930","article-title":"Finasteride induced gynecomastia: case report and review of the literature","volume":"1","author":"Ramot","year":"2009","journal-title":"Int J Trichology"},{"key":"10.1016\/j.clbc.2019.04.006_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1464-410X.1996.00091.x","article-title":"The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients","volume":"78","author":"Wilton","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.clbc.2019.04.006_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2013.10.049","article-title":"A\u00a0randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia","volume":"70","author":"Gubelin Harcha","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clbc.2019.04.006_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.138.4.533","article-title":"Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride","volume":"138","author":"Ferrando","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clbc.2019.04.006_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cam4.1273","article-title":"Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries","volume":"7","author":"Meijer","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0024-3205(02)01627-2","article-title":"Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride","volume":"71","author":"Ranjan","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.clbc.2019.04.006_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0960-0760(94)90145-7","article-title":"Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2","volume":"48","author":"Levy","year":"1994","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.clbc.2019.04.006_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/CLEP.S124674","article-title":"Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia","volume":"9","author":"Hagberg","year":"2017","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.clbc.2019.04.006_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.clbc.2019.04.006_bib20","doi-asserted-by":"crossref","first-page":"f2109","DOI":"10.1136\/bmj.f2109","article-title":"Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study","volume":"346","author":"Toren","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2019.04.006_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/11593750-000000000-00000","article-title":"Efficacy and safety of dutasteride in chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension","volume":"32","author":"Na","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clbc.2019.04.006_bib22","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.urology.2009.06.067","article-title":"The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial)","volume":"74","author":"Bepple","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.clbc.2019.04.006_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clbc.2019.04.006_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(02)02548-7","article-title":"Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia","volume":"61","author":"Lowe","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clbc.2019.04.006_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib27","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia","volume":"338","author":"McConnell","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group","volume":"327","author":"Gormley","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2019.04.006_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bju.13033","volume":"116","author":"Roehrborn","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.clbc.2019.04.006_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1442-2042.2012.03091.x","article-title":"Comparison of the response to treatment between asian and caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study","volume":"19","author":"Chung","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.clbc.2019.04.006_bib32","first-page":"303","article-title":"Efficacy of finasteride in treating benign prostatic hyperplasia","volume":"15","author":"Jing","year":"2010","journal-title":"J\u00a0Mod Urol"},{"key":"10.1016\/j.clbc.2019.04.006_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/pcan.2008.49","article-title":"Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH","volume":"12","author":"Chung","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clbc.2019.04.006_bib34","first-page":"915","article-title":"Inhibitors of 5-alpha reductase related side effects in patients seeking medical care for sexual dysfunction","volume":"35","author":"Corona","year":"2012","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.clbc.2019.04.006_bib35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU International"},{"year":"2015","series-title":"Gynecomastia: Etiology, Diagnosis, and Treatment","author":"Swerdloff","key":"10.1016\/j.clbc.2019.04.006_bib36"},{"key":"10.1016\/j.clbc.2019.04.006_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/smrj.3","article-title":"Side effects of 5-alpha reductase inhibitors: a comprehensive review","volume":"1","author":"Trost","year":"2013","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.clbc.2019.04.006_bib38","first-page":"1811","article-title":"Male breast cancer and 5\u03b1-reductase inhibitors finasteride and dutasteride","volume":"190","author":"Bird","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clbc.2019.04.006_bib39","first-page":"1289","article-title":"5-\u03b1 reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer","volume":"26","author":"Robinson","year":"2015","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clbc.2019.04.006_bib40","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1023\/B:CACO.0000036154.18162.43","article-title":"Alcohol drinking may increase risk of breast cancer in men: a European population-based case\u2013control study","volume":"15","author":"Gu\u00e9nel","year":"2004","journal-title":"Cancer Causes & Control"},{"key":"10.1016\/j.clbc.2019.04.006_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/01.sap.0000245118.98550.cf","article-title":"Incidental discovery of bilateral breast cancer in a 24-year-old man presenting with gynecomastia","volume":"58","author":"Liao","year":"2007","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.clbc.2019.04.006_bib42","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918308371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918308371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:57Z","timestamp":1761513537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820918308371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1526820918308371"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2019.04.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}